Answer
Yes, rare cases of aplastic anaemia, including fatal events, have been reported with osimertinib mesylate (Tagrisso), and Tagrisso should be discontinued if aplastic anaemia is confirmed.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.8 Undesirable effects · Version 33Document updated
Sources checked